<DOC>
	<DOC>NCT02926976</DOC>
	<brief_summary>The Optimal Treatment for Treatment-resistant Schizophrenia</brief_summary>
	<brief_title>The Optimal Treatment for Treatment-resistant Schizophrenia</brief_title>
	<detailed_description>To explore the curative effect and safety of Risperidone，aripiprazole，sodium valproate，modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with Clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for clinical medication.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>The diagnosis of schizophrenia according to DSMV 18～60 years old 2 prior failed treatment trials with 2 different antipsychotics at doses of at least 600 mg/day chlorpromazine equivalents, each of at least 6 weeks duration; Signed an informed consent patients to be diagnosed according to DSMV for substance abused, development delayed suffering from serious physical disease and can not accept the treatment MST contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure allergic to risperidone ,aripiprazole, or sodium valproate Participated in any clinical subject within 30 days Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>